DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
Follow DXCM
Alert me
DexCom, Inc. (DXCM) P/B ratio
As of 5 November 2026, DexCom, Inc. (DXCM) trades at a P/B ratio of 12.5×. Over the past ten years it has ranged from 7.5× (April 2026) to 47.5× (September 2015); the current reading is higher than 14% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 9.4× | (35.22%) |
| FY2024 | 14.6× | (36.62%) |
| FY2023 | 23.0× | 9.60% |
| FY2022 | 21.0× | (17.60%) |
| FY2021 | 25.4× | 33.14% |
| FY2020 | 19.1× | (15.40%) |
| FY2019 | 22.6× | 41.74% |
| FY2018 | 15.9× | 33.48% |
| FY2017 | 11.9× | (30.43%) |
| FY2016 | 17.2× | (41.95%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 12.8× | 29.87% |
| Jun 2026 | 9.8× | 20.06% |
| Mar 2026 | 8.2× | (13.28%) |
| Dec 2025 | 9.4× | (2.31%) |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| ZBH Zimmer Biomet Holdings, Inc. compare | 1.6× |
| PHG Koninklijke Philips N.V. compare | 2.2× |
| BSX Boston Scientific Corporation compare | 2.5× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.8× |
| GEHC GE HealthCare Technologies Inc. compare | 3.2× |
| STE STERIS plc compare | 3.4× |
| EW Edwards Lifesciences Corporation compare | 5.3× |
| DXCM DexCom, Inc. | 12.5× |
| GKOS Glaukos Corporation compare | 18.1× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement